(Q48027994)

7 February 2018

title

Cost-effectiveness analysis of abciximab: a Canadian hospital perspective (English)

1 reference

7 February 2018

author name string

P J Zed

1

1 reference

7 February 2018

L Frighetto

2

1 reference

7 February 2018

R Sunderji

3

1 reference

7 February 2018

C A Marra

4

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 May 1998

1 reference

7 February 2018

Annals of Pharmacotherapy

published in

1 reference

7 February 2018

volume

32

1 reference

7 February 2018

issue

5

1 reference

7 February 2018

page(s)

536-542

1 reference

7 February 2018

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

cites work

1 reference

Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris

21 January 2018

1 reference

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

21 January 2018

1 reference

Advances in coronary angioplasty

21 January 2018

1 reference

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous T

21 January 2018

1 reference

The generalisability of pharmacoeconomic studies

21 January 2018

1 reference

Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis

21 January 2018

1 reference

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

21 January 2018

1 reference

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

21 January 2018

1 reference

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

21 January 2018

1 reference

Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile

21 January 2018

1 reference

Long-term outcome following successful reopening of abrupt closure after coronary angioplasty

21 January 2018

1 reference

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.17336

1 reference

7 February 2018

1 reference

7 February 2018